François Spézia
François Spézia publishes mostly in Molecular Biology, Pediatrics, Perinatology and Child Health and Health, Toxicology and Mutagenesis, on topics such as Effects and risks of endocrine disrupting chemicals, Carcinogens and Genotoxicity Assessment and Peroxisome Proliferator-Activated Receptors.
- World rank
- #6,408,659 of 7,710,434 ranked researchers
- Rank in Slovenia
- #7,801 of 9,404
- Works
- 23
- Citations
- 168
- Citations per work
- 7.3
What does François Spézia research?
François Spézia's work is mostly in Biochemistry, Genetics and Molecular Biology (23%), Medicine (20%), Environmental Science (8%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Everything else1149.2%
- Life Sciences522.9%
- Health Sciences519.7%
- Medicine519.7%
- Physical Sciences28.2%
- 1Molecular Biology18% of their works
- 2Pediatrics, Perinatology and Child Health8% of their works
- 3Health, Toxicology and Mutagenesis8% of their works
- 4Public Health, Environmental and Occupational Health8% of their works
- 5Cancer Research5% of their works
- 6Oncology3% of their works
Research topics
- Effects and risks of endocrine disrupting chemicals
- Carcinogens and Genotoxicity Assessment
- Peroxisome Proliferator-Activated Receptors
- Plant Toxicity and Pharmacological Properties
- Renal and related cancers
- Cardiovascular Issues in Pregnancy
- Pregnancy and preeclampsia studies
- Drug Transport and Resistance Mechanisms
Which keywords describe François Spézia's research?
The keywords of their largest research topics: Bisphenol A, Endocrine-Disrupting Chemicals, Risk Assessment, Metabolism, Nuclear Receptors, Comet Assay, Genotoxicity Testing and ATP-dependent Transporters.
- Pyrrolizidine Alkaloids
- Preeclampsia
- Peroxisome Proliferator-Activated Receptors
- Nephrogenesis
- Kidney Organoids
- ATP-dependent Transporters
- Comet Assay
- Metabolism
- Endocrine-Disrupting Chemicals
- Bisphenol A
- Risk Assessment
- Nuclear Receptors
- Genotoxicity Testing
- Cardiovascular Diseases
- Multidrug Resistance
- PPARs
- Placental Development
- Pregnancy
- Toxicity
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.
All 19 words, with their numbers
- Bisphenol A51 topic
- Endocrine-Disrupting Chemicals51 topic
- Risk Assessment52 topics
- Metabolism42 topics
- Nuclear Receptors42 topics
- Comet Assay31 topic
- Genotoxicity Testing31 topic
- ATP-dependent Transporters21 topic
- Cardiovascular Diseases21 topic
- Kidney Organoids21 topic
- Multidrug Resistance21 topic
- Nephrogenesis21 topic
- PPARs21 topic
- Peroxisome Proliferator-Activated Receptors21 topic
- Placental Development21 topic
- Preeclampsia21 topic
- Pregnancy21 topic
- Pyrrolizidine Alkaloids21 topic
- Toxicity21 topic
Where does François Spézia work?
François Spézia's main affiliation in the publication record is XLAB (Slovenia), Slovenia.
How many publications and citations does François Spézia have?
OpenAlex counts 23 works and 168 citations for François Spézia, an h-index of 6, ranking #6,408,659 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about François Spézia. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.